undamentalytics Newsletter

Maze Therapeutics, Inc. valuation and forecast

Explore the models for Maze Therapeutics, Inc., adjust their assumptions and compare your own valuation with the platform's.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Maze Therapeutics, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: limited reported history: available models are shown without a Buy/Hold/Sell rating. We'll show the comparison once resolved.

Analyst recommendations

14 analysts, Oct 2026
Buy14100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202611314
  2. Sep 202611213
  3. Aug 202611112
  4. Jul 202611112

Counts of recommendations published by analysts covering Maze Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Price history

Loading chart…

Third-party market data · may be delayed

MAZE valuation questions

How does Fundamentalytics value Maze Therapeutics, Inc.?
We use the models that fit Maze Therapeutics, Inc.'s business and available financial data. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.

Data: SEC EDGAR filings, retrieved Invalid Date. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Maze Therapeutics, Inc.